Response and Resistance to BCR-ABL1-Targeted Therapies
Author:
Funder
Howard Hughes Medical Institute
Publisher
Elsevier BV
Subject
Cancer Research,Cell Biology,Oncology
Reference150 articles.
1. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects;Abbas;Cancer Chemother. Pharmacol.,2012
2. PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor;Airiau;Cell Death Dis.,2013
3. Acquired resistance to crizotinib from a mutation in CD74–ROS1;Awad;N. Engl. J. Med.,2013
4. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells;Bellodi;J. Clin. Invest.,2009
5. Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission;Bocchia;Front. Oncol.,2018
Cited by 293 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Novel ABL1 mutation in a Moroccan CML patient with Imatinib resistance;Cancer Genetics;2024-11
2. Two cases of imatinib induced oral pigmentation affecting the palate;Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology;2024-10
3. Novel targeted therapies in chronic myeloid leukemia;Pharmaceutical Science Advances;2024-09
4. Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia;Oncohematology;2024-09-01
5. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3